Literature DB >> 12355442

Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells.

Claire N Manzotti1, Helen Tipping, Laura C A Perry, Karen I Mead, Patrick J Blair, Yong Zheng, David M Sansom.   

Abstract

CD28 and CTLA-4 are opposing regulators of T cell activation, triggered by the two ligands CD80 and CD86. How these ligands promote either T cell activation via CD28 or inhibition via CTLA-4 is not understood. Using CD80 and CD86 molecules expressed on transfected cells, we have identified a major difference between these ligands in that CD80 transfectants have the ability to inhibit activation of resting human peripheral blood T cells via interaction with CTLA-4, whereas CD86 transfectants do not. Rather, CTLA-4-CD86 interactions appear to contribute towards T cell proliferation. We also observed that CTLA-4 function is strongly influenced by TCR stimulation, effects being observed only at relatively low levels of TCR stimulation. The kinetics of CD80-CTLA-4 interactions revealed that CTLA-4 inhibition took place within the first 8 h of T cell stimulation, despite there being little measurable CTLA-4 expression on the majority T cells. However, significant amounts of CTLA-4 were observed in the CD25(+) CD4(+) subset of T cells which, when removed from the cultures, accounted for the CTLA-4 inhibition observed. Overall, these data provide evidence that CD80 and CD86 differ in their interactions with CTLA-4 and that CD80 appears to be the preferential inhibitory ligand for CTLA-4 working via a population of CD4(+) CD25(+) CTLA-4(+) regulatory T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355442     DOI: 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  40 in total

1.  Identification of a unique double-negative regulatory T-cell population.

Authors:  Byung O Lee; Joyce E Jones; Cory J Peters; David Whitacre; Lars Frelin; Janice Hughes; Won-Keun Kim; David R Milich
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

Review 2.  Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Authors:  Hélène Bour-Jordan; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 3.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

4.  Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation.

Authors:  Nicolas Perez; Subha Karumuthil-Melethil; Ruobing Li; Bellur S Prabhakar; Mark J Holterman; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  Aberrant expression of costimulatory molecules in splenocytes of the mevalonate kinase-deficient mouse model of human hyper-IgD syndrome (HIDS).

Authors:  Elizabeth J Hager; Jon D Piganelli; Hubert M Tse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2011-05-24       Impact factor: 4.982

6.  Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta analysis.

Authors:  Lijie Wang; Fangfang Jing; Dan Su; Tingting Zhang; Bo Yang; Shunchang Jiao; Yi Hu; Li Bai
Journal:  Int J Clin Exp Med       Date:  2015-01-15

7.  Autoantigen Tetramer Silences Autoreactive B Cell Populations.

Authors:  Matthew A Christopher; Stephanie N Johnson; J Daniel Griffin; Cory J Berkland
Journal:  Mol Pharm       Date:  2020-10-06       Impact factor: 4.939

8.  Foxp3 expression in p53-dependent DNA damage responses.

Authors:  Da-Jung Jung; Dong-Hoon Jin; Seung-Woo Hong; Jee-Eun Kim; Jae-Sik Shin; Daejin Kim; Byung-Joo Cho; Young-Il Hwang; Jae-Seung Kang; Wang-Jae Lee
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 9.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

10.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.

Authors:  Eric Toussirot; Philippe Saas; Marina Deschamps; Fabienne Pouthier; Lucille Perrot; Sylvain Perruche; Jacqueline Chabod; Pierre Tiberghien; Daniel Wendling
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.